| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Institute for Human Gene Therapy and Departments of Medicine and of Molecular and Cellular Engineering, University of Pennsylvania, and Wistar Institute, Philadelphia, PA 19104; and
Department of Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406
The central role of CD4+ T cells in regulation of adenovirus vector-mediated immune responses has been documented previously in murine models. We analyzed the effects of a nondepleting mAb to human CD4 (CD4 mAb; Clenoliximab) on immune functions following intratracheal administration of adenoviral vectors in murine CD4-deficient mice (muCD4KO) expressing a human CD4 transgene (HuCD4 mice). Treatment of HuCD4 mice with Clenoliximab inhibited both cell-mediated and humoral immune responses to adenoviral Ags. Chronic treatment of HuCD4 mice with Clenoliximab permitted successful readministration of adenoviral vectors at least four times. The ability to readminister these vectors is associated with marked suppression of neutralizing Ab responses to viral capsid proteins. Clenoliximab also inhibited CTL and prolonged expression of the transgene. T or B cell responses to adenovirus did not emerge after the effects of a short course of Clenoliximab diminished. These data illustrate the potential utility of a nondepleting CD4 Ab in facilitating gene therapy using adenoviral vectors.
This article has been cited by other articles:
|
|
 |
|
  A. Keriel, C. Rene, C. Galer, J. Zabner, and E. J. Kremer Canine Adenovirus Vectors for Lung-Directed Gene Transfer: Efficacy, Immune Response, and Duration of Transgene Expression Using Helper-Dependent Vectors J. Virol., February 1, 2006; 80(3): 1487 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sun, F. Bodola, X. Fan, H. Irshad, L. Soong, S. M. Lemon, and T.-S. Chan Hepatitis C Virus Core and Envelope Proteins Do Not Suppress the Host's Ability To Clear a Hepatic Viral Infection J. Virol., December 15, 2001; 75(24): 11992 - 11998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Lindsay, C. J. Ciesielski, T. Scheinin, H. J. Hodgson, and F. M. Brennan The Prevention and Treatment of Murine Colitis Using Gene Therapy with Adenoviral Vectors Encoding IL-10 J. Immunol., June 15, 2001; 166(12): 7625 - 7633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Croyle, N. Chirmule, Y. Zhang, and J. M. Wilson "Stealth" Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung J. Virol., May 15, 2001; 75(10): 4792 - 4801. [Abstract] [Full Text]
|
|
|
|
|
|
P. Ostapchuk and P. Hearing Pseudopackaging of Adenovirus Type 5 Genomes into Capsids Containing the Hexon Proteins of Adenovirus Serotypes B, D, or E J. Virol., January 1, 2001; 75(1): 45 - 51. [Abstract] [Full Text]
|
|
|
|
|
|
N. Chirmule, S. E. Raper, L. Burkly, D. Thomas, J. Tazelaar, J. V. Hughes, and J. M. Wilson Readministration of Adenovirus Vector in Nonhuman Primate Lungs by Blockade of CD40-CD40 Ligand Interactions J. Virol., April 1, 2000; 74(7): 3345 - 3352. [Abstract] [Full Text]
|
|
|
|
|
|
N. Chirmule, W. Xiao, A. Truneh, M. A. Schnell, J. V. Hughes, P. Zoltick, and J. M. Wilson Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle J. Virol., March 1, 2000; 74(5): 2420 - 2425. [Abstract] [Full Text]
|
|
|
|
|
|
N. Chirmule, J. Tazelaar, and J. M. Wilson Th2-Dependent B Cell Responses in the Absence of CD40-CD40 Ligand Interactions J. Immunol., January 1, 2000; 164(1): 248 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Qian, K. Channon, V. Neplioueva, Q. Wang, M. Finer, L. Tsui, S. E. George, and J. McArthur Improved Adenoviral Vector for Vascular Gene Therapy : Beneficial Effects on Vascular Function and Inflammation Circ. Res., May 11, 2001; 88(9): 911 - 917. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
